AstraZeneca says Imfinzi combo doubles OS rate in late-stage BTC trial
AstraZeneca said that Imfinzi (durvalumab) in combination with standard-of-care chemotherapy doubled the overall survival (OS) rate at three years for patients with advanced biliary tract cancer (BTC) in